Purity ≥98%. A nonsteroidal aromatase inhibitor structurally related to Fadrozole. Antineoplastic. An orally bioavailable non-steroidal triazole compound that acts as a potent and selective inhibitor of aromatase (IC50=140, 350 and 450pM in Dex-treated fibroblasts, MCF-7Ca, and JEG-3 cells, respectively). Competitively, but reversibly binds to the heme iron of aromatase. Does not affect the synthesis of adrenal mineralocorticoid or glucocorticoids. Reported to be highly effective as an anti-estrogenic and anti-proliferative agent in estrogen-rich tumors. Also delays the fusing of the growth plates in adolescents and enhances the effectiveness of growth hormone. Shown to synergistically induce apoptosis and cause tumor regression when combined with IGF-1R inhibitors. Synonyms: 4,4'-(1H-1,2,4-Triazol-1-ylmethylene)bisbenzonitrile; 4-[1-(4-Cyanophenyl)-1-(1,2,4-triazol-1-yl)methyl]benzonitrile; CGS 20267; Femara; Lerozole; Letrazole; Aromatase Inhibitor II CAS No: 112809-51-5
Size
1g, 5g
Concentration
n/a
Applications
n/a
Other Names
4,4'-(1H-1,2,4-Triazol-1-ylmethylene)bisbenzonitrile; 4-[1-(4-Cyanophenyl)-1-(1,2,4-triazol-1-yl)methyl]benzonitrile; CGS 20267; Femara; Lerozole; Letrazole; Aromatase Inhibitor II